---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-024935"
form_type: "8-K"
ticker: null
cik: "0000793171"
company_name: "Vitro Biopharma, Inc."
filed_at: "2023-07-19T23:59:59+00:00"
generated_at: "2026-06-13T06:42:40.404323+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Vitro Biopharma issues $100K 8% convertible note with warrants to accredited investor

## Summary
- Sold $100,000 8% convertible promissory note to accredited investor; total proceeds $100,000.
- Note matures in 5 years; converts at qualified financing (≥$5M) or change of control at discounted or capped price.
- Capped price based on $200M pre-money valuation; discounted price is 75% of qualified financing price.
- Warrants to purchase shares at $0.625/share for 5 years; holder may participate in future qualified financing up to 200% of note principal.
- Securities sold under Rule 506 exempt registration; resale restrictions apply.

## SEC filing metadata
- accession: 0001493152-23-024935
- form_type: 8-K
- cik: 0000793171
- company_name: Vitro Biopharma, Inc.
- filed_at: 2023-07-19T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/793171/000149315223024935/0001493152-23-024935-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/793171/000149315223024935/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-024935
- JSON: https://secwatch.observer/filing/0001493152-23-024935.json
- Plain text: https://secwatch.observer/filing/0001493152-23-024935.txt

## Key facts
- Debt Financings
  Vitro Biopharma, Inc. incurred convertible notes of $100,000 at eight per cent per year maturing five years from the date of issuance.
  - Instrument: convertible notes
  - Principal: $100,000
  - Rate: eight per cent per year
  - Maturity: five years from the date of issuance
  - Event: incurrence
  source text: On July 13, 2023, Vitro Biopharma, Inc. (the “Company”) entered into definitive agreements with an accredited investor for the sale of an 8% convertible promissory note (the “Convertible Note”) in the principal amount of $100,000 and warrants to purchase shares of common stock of the Company (the “Warrants”) for total proceeds of $100,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/793171/000149315223024935/0001493152-23-024935-index.htm
- Material Agreements
  Vitro Biopharma, Inc. entered into Convertible Note and Warrant Purchase Agreement with accredited investor valued at $100,000 convertible promissory note and warrants for total proceeds of $100,000 (effective 2023-07-13).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: accredited investor
  - Value: $100,000 convertible promissory note and warrants for total proceeds of $100,000
  - Effective: 2023-07-13
  source text: On July 13, 2023, Vitro Biopharma, Inc. (the "Company") entered into definitive agreements with an accredited investor for the sale of an 8% convertible promissory note (the "Convertible Note") in the principal amount of $100,000 and warrants to purchase shares of common stock of the Company (the "Warrants") for total proceeds of $100,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/793171/000149315223024935/0001493152-23-024935-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.